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In patients with chronic kidney disease, high plasma levels of
the endogenous nitric oxide synthase inhibitor, asymmetric
dimethylarginine, are thought to contribute to decline in renal
function. Here we took a candidate gene approach to
determine any causal role of asymmetric dimethylarginine in
the progression of chronic kidney disease. The impact of
single-nucleotide polymorphisms in the genes encoding the
two isoforms of the asymmetric dimethylarginine-degrading
enzyme, dimethylarginine dimethylaminohydrolase (DDAH1
and DDAH2), on enzyme expression, plasma asymmetric
dimethylarginine levels, and longitudinal changes in
estimated glomerular filtration rate were determined in
various patient groups. There was evidence suggesting that
the rs17384213 DDAH1 GG genotype was associated with
increased expression of its mRNA in kidney allografts. Healthy
subjects carrying the rs17384213 G allele had lower plasma
asymmetric dimethylarginine, and a similar borderline
association was found in patients with chronic kidney disease.
This allele, however, was independently associated with
a steeper decline in renal function in two separate cohorts
of patients with chronic kidney disease. We conclude
that polymorphisms in DDAH1 alter the rate of decline
of glomerular filtration rate in subjects with chronic kidney
disease. Our findings show that DDAH1 modulates plasma
asymmetric dimethylarginine and contributes to the decline
in renal function. However, it appears that increases in
circulating methylarginine did not mediate progressive
kidney injury.
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Although the causes of chronic kidney disease (CKD) are
diverse, progressive loss of kidney function, associated with
proteinuria and hypertension, is characteristic, even when the
underlying cause of renal injury has been successfully treated
or has resolved spontaneously.1 Current therapy, directed at
this common pathway of decline in renal function, is limited
to agents to control blood pressure (BP) and proteinuria.2 A
better understanding of the common mechanisms underlying
disease progression is therefore essential.
The endogenous nitric oxide synthase inhibitor, asym-
metric dimethylarginine (ADMA), first described by Vallance
et al.3 in the early 1990s, accumulates in patients with end-
stage renal failure. Observational studies in CKD have shown
an inverse association between plasma ADMA and kidney
function, as measured by the estimated glomerular filtration
rate (eGFR).4,5 These studies have also described a relation-
ship between circulating ADMA concentrations and adverse
renal outcomes over time, independent of baseline eGFR,4,5
which could imply a causal role for elevated ADMA levels in
the progressive decline in kidney function. However increased
plasma levels of ADMA have also been reported in association
with a number of disease states and vascular risk factors,
including but not limited to liver disease,6 vascular disease,7
diabetes,8 hypertension,9 aging,9 dyslipidemia,7,10 hyperhomo-
cysteinemia,10 and smoking.10 The observational evidence for
any causal effect of ADMA in the progression of CKD is
therefore difficult to interpret, given the number of potential
confounders and the possibility of reverse causation.
Asymmetric dimethylarginine is metabolized by the
two isoforms of dimethylarginine dimethylaminohydrolase
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(DDAH), which are expressed in a number of human tissues
including the kidney,11 and are thought to be jointly
responsible for the degradation of 480% of ADMA in
vivo.12 Although two rodent models have suggested that
non-tissue-specific increases in DDAH1 can lead to the
amelioration of kidney injury,13,14 the applicability of these
experimental models to the clinical disorder is unclear.
To further evaluate a role for ADMA in the progression of
CKD in humans, we used the variation in the genes (single
nucleotide polymorphisms, SNPs) encoding the DDAHs as
genetic instruments, which are less prone to spurious
confounding or reverse causation.15 The aim of this study
was to investigate whether genetic variation in DDAH1
and/or DDAH2 (1) modulated DDAH transcription in
human kidney tissue, (2) altered plasma ADMA concentra-
tions in healthy subjects and/or CKD patients in a cross-
sectional analysis, and (3) was related to decline in kidney
function over time in subjects with CKD.
The multivariate modeling of quantitative traits over time
in cohorts diagnosed with specific diseases such as CKD, as
well as the measurement of metabolites using high-perfor-
mance liquid chromatography, is not practical in studies
including more than several hundred subjects. Therefore, we
took a candidate gene approach and confirmed our findings
in independent groups to address the potential false discovery
rate due to multiple testing.
To address whether SNPs altered gene expression, we
investigated the relationship between kidney transplant
donor DDAH genotypes and recipient allograft DDAH
mRNA from protocol biopsy samples. To assess the impact
of DDAH SNPs on plasma ADMA levels, we conducted
analyses on baseline samples from both the European
Atherosclerosis Relatives Study II (EARSII) and the London
Arterial Calcification, Kidney and Bone Outcomes
(LACKABO) cohort. To investigate the relationship between
DDAH gene variation and eGFR, we performed primary
analysis in the LACKABO cohort followed by independent
confirmatory analysis at selected loci in the Chronic Renal
Insufficiency Standards Implementation Study (CRISIS) cohort.
RESULTS
DDAH1 and DDAH2 mRNA levels
In transplant donors, five SNPs were genotyped as donor
DNA availability was limited. There was an increase in
normalized DDAH1 mRNA in the protocol biopsies of
allografts from donors homozygous for the rs17384213 G
allele compared to the combined group of heterozygotes
and homozygous A (difference in means 0.37 arbitrary units;
95% confidence intervals (CIs), 0.01–0.72; Figure 1a). Donor
genotype at the other loci in DDAH1 (rs7555486, rs1146381,
and rs233112) and DDAH2 (rs805304) had no impact on
respective allograft mRNA levels (Supplementary Table 1).
Cohorts
The demographics and baseline characteristics of the EARSII
participants, and white subjects in the LACKABO and CRISIS
cohorts are outlined in Table 1. In the LACKABO study larger
numbers of subjects had been given a diagnosis of ‘polycystic
kidney disease’, ‘dysplastic or refluxing renal diseases’, and
‘other renal diseases’. Conversely, subjects were more likely
to be labeled as having a diagnosis of ‘hypertensive and
renovascular’ or ‘renal disease of unknown cause’ in CRISIS.
Subjects were significantly older, eGFR at recruitment was
lower, and median follow-up longer in CRISIS (Table 1).
No follow-up data were available for 9 subjects in LACKABO
and 27 subjects in CRISIS.
Genotyping
Six (three in CRISIS) loci in DDAH1 and one locus in
DDAH2 were examined (Table 2). Together these poly-
morphisms tag 54% of common polymorphic alleles within
DDAH1 (Figure 2) and the entire common variation in
DDAH2.16 Genotype frequencies in the EARSII, LACKABO,
and CRISIS studies are shown in Table 2. The call rates,
Hardy–Weinberg P-value at each SNP and linkage disequili-
brium between the loci within each of the three study groups
are all presented in Supplementary Table 2. No differences
were observed in genotype frequencies between cohorts
except at rs17384213 where the AA genotype was more
prevalent in the LACKABO cohort (P¼ 0.04 using w2-test).
All loci were in Hardy–Weinberg equilibrium.
Plasma ADMA
The geometric mean of the plasma ADMA concentrations
was higher in the LACKABO cohort (0.68 mmol/l; 95% CI,
0.64–0.73) than in the EARSII study (0.38 mmol/l; 95% CI,
0.37–0.39). DDAH1 genotype was associated with plasma
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Figure 1 | Impact of the DDAH1 SNP rs17384213 on
renal allograft mRNA expression and circulating ADMA
concentrations. (a) Renal allograft DDAH1 mRNA levels stratified
according to genotype at DDAH1 SNP rs17384213. DDAH1
mRNA values normalized to the geometric mean of b-actin,
b2-microglobulin, and TATA-box binding protein. Horizontal bars:
arithmetic mean. (b) Adjusted plasma asymmetric
dimethylarginine (ADMA) concentrations in the European
Atherosclerosis Relatives Study II (EARSII) and the London Arterial
Calcification, Kidney and Bone Outcomes (LACKABO) subjects
stratified by genotype at rs17384213. Plasma ADMA values were
adjusted for age in LACKABO and age, case–control status and
region of origin in EARSII. Solid bars, EARSII; hatched bars,
LACKABO; y axis, log scale. Geometric mean of adjusted ADMA
levels is shown; error bars, standard error of the geometric mean.
No formal correction for multiple testing was made.
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ADMA concentrations in EARSII participants at several loci
(Table 3). Specifically, healthy men in the EARSII study
carrying the rs17384213 G allele had lower plasma ADMA
compared with those with the AA genotype (P¼ 0.020;
Figure 1b). A similar trend was observed in the white subjects
of the LACKABO cohort (P¼ 0.050; Figure 1b). There was
no evidence for a correlation between eGFR and log-
transformed ADMA concentrations in LACKABO subjects
(r¼0.096, P¼ 0.22). The results of an analysis of ADMA in
LACKABO using a model that included age, sex, and a
genotype sex interaction are presented in Supplementary
Table 3 but should be interpreted with caution given the very
low numbers of subjects in the rare homozygous group when
stratified by sex.
Change in eGFR over time
The baseline multilevel model (LACKABO and CRISIS)
describing eGFR through the follow-up period included sex,
age, time, urinary protein excretion (UPE) and an interaction
term: UPE time (Table 4). The mean decline in eGFR in
those subjects without proteinuria was comparable between
the two CKD cohorts (LACKABO, 0.83ml/min per 1.73m2
per year; 95% CI, 1.80 to 0.14; CRISIS, 1.33ml/min per
1.73m2 per year, 95% CI, 1.66 to 1.00). Although the
coefficients are not directly comparable as the units of
Table 2 | Genotype frequencies at the SNP loci in DDAH1 and
DDAH2
Genotype frequencies
EARSII LACKABO CRISIS
DDAH2
rs805304, DDAH2:g.22556339T4G, n (%)
AA 312 (41.7) 77 (44.0) 319 (38.4)
AC 334 (44.7) 73 (41.7) 400 (48.1)
CC 102 (13.6) 25 (14.3) 112 (13.5)
DDAH1
rs7555486, DDAH1:g.55890889T4A, n (%)
TT 379 (49.7) 102 (57.0) 439 (53.6)
AT 321 (42.1) 67 (37.4) 312 (38.1)
AA 63 (8.3) 10 (5.6) 68 (8.3)
rs1146381, DDAH1:g.55883209A4G, n (%)
AA 211 (27.9) 51 (27.9) 221 (26.4)
AG 369 (48.9) 92 (50.3) 404 (48.3)
GG 175 (23.2) 40 (21.9) 211 (25.2)
rs17384213, DDAH1:g.55856540G4A, n (%)
GG 524 (69.6) 104 (59.8) 602 (72.6)
AG 201 (26.7) 60 (34.5) 204 (24.6)
AA 28 (3.7) 10 (5.7) 23 (2.8)
rs233128, DDAH1:g.55766332G4C, n (%)
GG 373 (50.3) 85 (46.2)
CG 316 (42.6) 79 (42.9)
CC 52 (7.0) 20 (10.9)
rs11161614, DDAH1:g.55870079T4G, n (%)
TT 462 (61.4) 121 (67.2)
GT 261 (34.7) 50 (27.8)
GG 30 (4.0) 9 (5.0)
rs233112, DDAH1:g.55757670T4C, n (%)
TT 311 (41.0) 70 (39.1)
CT 336 (44.3) 83 (46.4)
CC 111 (14.6) 26 (14.5)
Abbreviations: CRISIS, Chronic Renal Insufficiency Standards Implementation
Study; EARSII, European Atherosclerosis Relatives Study II; LACKABO, London
Arterial Calcification, Kidney and Bone Outcomes. White subjects only. Database
accession numbers: DDAH2, NT_007592.14; DDAH1, NT_032977.8
Table 1 | Demographics of the participants in the EARSII,
LACKABO, and CRISIS studies
EARSII,
n=822
LACKABOa,
n=189
CRISISa,
n=856
Male, n (%) 822 (100) 132 (69.8) 577 (67.4)
Diabetes, n (%) 31 (16.4) 256 (29.9)
Renal disease, n (%)b
Cystic disease 20 (10.6) 47 (5.5)
Diabetes 19 (10.1) 98 (11.4)
Dysplastic/reflux 13 (6.9) 22 (2.6)
GN 18 (9.5) 151 (17.6)
Hyp/RV 14 (7.4) 142 (16.2)
Other 72 (38.1) 139 (16.6)
Unknown 33 (17.5) 257 (30.0)
Age at recruitment, years
Mean 22.9 57.3 64.9
95% CI 22.7–23.1 55.1–59.5 63.9–65.8
Follow-up time, days
Median 555 1204
Range 35–1191 31–2151
SBP, mmHg
Mean 116.9 131.5 140.8
95% CI 116.2–117.6 128.8–134.3 139.3–142.3
DBP, mmHg
Mean 73.5 78.8 78.7
95% CI 72.8–74.2 77.1–80.4 77.9–79.6
Antihypertensives, number
Mean 2.3 2.4
95% CI 2.1–2.5 2.3–2.5
eGFR at recruitment, ml/min per 1.73m2
Mean 39.2 33.5
95% CI 36.9–41.5 32.5–34.5
Urinary protein, mg/mmol (LACKABO), g/24 h (CRISIS)
Median 62.5 0.4
IQR 17.5–128.5 0.2–1.1
Plasma ADMA, mmol/l
Median 0.39 0.67
IQR 0.35–0.43 0.55–0.87
Abbreviations: ADMA: asymmetric dimethylarginine; CRISIS, Chronic Renal Insufficiency
Standards Implementation Study; DBP, diastolic blood pressure; EARSII, European
Atherosclerosis Relatives Study II; eGFR, estimated glomerular filtration rate; GN,
glomerulonephritis; Hyp, hypertension; IQR, interquartile range; LACKABO, London
Arterial Calcification, Kidney and Bone Outcomes; RV, renovascular disease; SBP,
systolic blood pressure.
aWhite-only subgroups of LACKABO and CRISIS.
bThe Royal Free Hampstead NHS Trust (LACKABO study) provides nephrology
follow-up for several supraregional referral centers, including those specializing in
adolescent urology, scleroderma, and amyloidosis.
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measurement differed, UPE was strongly associated with
eGFR decline as indicated by the UPE time interaction in
both LACKABO and CRISIS.
In the white subjects of both the LACKABO and CRISIS
cohorts, there were no associations between genotype at any
of the DDAH1 loci and either eGFR or age at recruitment,
cause of underlying renal disease, diabetes, systolic BP (SBP),
diastolic BP (DBP), number of antihypertensive medications,
survival, or numbers remaining free from the combined
outcome measure of death and end-stage renal failure. In the
LACKABO cohort, heterozygous subjects at rs233112 locus
had lower UPE than either homozygous group but UPE
did not differ between genotypes at any of the other loci.
An association between the DDAH2 SNP rs805304 CC
genotype and the presence of type 1 diabetes mellitus was
observed in the CRISIS cohort but this was not confirmed
in LACKABO.
Inclusion of DDAH1 genotype in the multilevel model
(Table 5) revealed an association between the rs17384213 G
allele and rate of decline of eGFR in white subjects of both
CKD cohorts. In LACKABO, the rs7555486 A allele was also
associated with rate of decline in eGFR but this was not
confirmed in the CRISIS cohort. There was no association
between the DDAH2 SNP rs805304 and eGFR decline when
added to the baseline model (Table 5).
As we only identified a consistent effect of gene variation
on eGFR decline at one locus, we did not conduct haplotype
analysis. Sensitivity analyses were conducted including the
variables SBP, DBP, number of antihypertensives, presence
of diabetes, and underlying renal disease along with the
respective interactions with time. Inclusion of these variables
did not substantially alter the model fit or coefficients for
the rs17384213 genotype time interaction. LogADMA and
logADMA time terms were not significantly associated with
eGFR when added to the genetic model in LACKABO and
did not substantially alter the coefficient of the rs17384213
genotype time term (Table 5).
DISCUSSION
In this study we show that genetic variation in DDAH1 is
associated with consistent effects on tissue levels of mRNA
in kidney allografts and plasma ADMA in humans. In two
independent cohorts of white subjects with CKD, variation
in DDAH1 is also associated with rate of decline in kidney
function, however the genotype associated with lower plasma
Table 3 | Adjusted plasma ADMA concentrations (geometric
mean and 95% CI) in LACKABO and EARSII by genotype
ADMA lmol/l geometric mean (95% CI)
EARSII LACKABOa
DDAH2
rs805304
AA 0.38 (0.37–0.39) 0.68 (0.62–0.74)
AC 0.38 (0.37–0.39) 0.64 (0.59–0.70)
CC 0.38 (0.36–0.39) 0.73 (0.63–0.86)
DDAH1
rs7555486
TT 0.39 (0.38–0.39) 0.69 (0.62–0.73)
AT 0.37 (0.36–0.38) 0.68 (0.62–0.76)
AA 0.37 (0.35–0.40) 0.57 (0.45–0.71)
rs1146381***
AA 0.39 (0.38–0.40) 0.71 (0.64–0.80)
AG 0.38 (0.37–0.39) 0.65 (0.60–0.70)
GG 0.37 (0.36–0.38) 0.67 (0.59–0.75)
rs17384213*
GG 0.38 (0.37–0.38) 0.67 (0.62–0.72)
AG 0.38 (0.37–0.39) 0.65 (0.59–0.72)
AA 0.42 (0.39–0.45) 0.90 (0.71–1.15)
rs233128*
GG 0.39 (0.38–0.39) 0.64 (0.59–0.70)
CG 0.37 (0.36–0.38) 0.71 (0.66–0.78)
CC 0.37 (0.35–0.39) 0.62 (0.52–0.74)
rs11161614**
TT 0.37 (0.36–0.38) 0.68 (0.63–0.72)
GT 0.40 (0.39–0.41) 0.66 (0.59–0.74)
GG 0.39 (0.37–0.42) 0.59 (0.42–0.82)
rs233112***
TT 0.37 (0.36–0.38) 0.67 (0.61–0.74)
CT 0.38 (0.37–0.39) 0.66 (0.61–0.72)
CC 0.41 (0.39–0.43) 0.72 (0.62–0.84)
Abbreviations: ADMA, asymmetric dimethylarginine; EARSII, European Atherosclerosis
Relatives Study II; LACKABO, London Arterial Calcification, Kidney and Bone Outcomes.
No formal correction for multiple testing was made. R2 for model of age-adjusted
logADMA at rs17384213 locus: EARSII, 0.02; LACKABO, 0.04.
*Po0.05 by analysis of variance (ANOVA) between genotypes in EARSII participants.
**Po0.01 by ANOVA between genotypes in EARSII participants.
***Po0.005 by ANOVA between genotypes in EARSII participants.
aWhite-only subjects in LACKABO.
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Figure 2 | Schematic representation and linkage
disequilibrium plot of DDAH1 showing the relative positions
of single-nucleotide polymorphisms (SNPs) examined in this
study. DDAH1 is located at chromosome 1p22 (reverse strand).
The rs17384213 polymorphism tags a significant portion of
intron 1. Base numbering from database accession number
NT_032977.8. Vertical bars, coding regions; black diamonds, SNPs.
Linkage disequilibrium from HAPMAP-CEU population shown;
plot adapted from Haploview software.16 Black, r2¼ 1; shades of
gray, 04r241; white, r2¼ 0. DDAH2 (chromosome 6p21) variation
is captured by a single SNP, rs805304.
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ADMA in health predicted faster decline in kidney function
in CKD. Although we also detected a difference between men
and women in the genotype–ADMA model including sex
and a sex genotype interaction, these findings should be
interpreted with caution as the LACKABO cohort lacks the
appropriate power to analyze this relationship when stratified
by sex.
Regulation of DDAH1 mRNA and ADMA levels through a
nonpromoter intronic sequence (a farnesoid X receptor
response element) has been reported in rodents.17 However,
there is no common variation in the analogous human
sequence reported in publicly available electronic databases,18
so it is unlikely that the changes in outcome associated with
the rs17384213 SNP are mediated through this particular
transcriptional regulation site. Although individuals carrying
rare coding mutations in DDAH1 have been reported to be
hypertensive,19 the nature of these genetic variants has not
been described in detail. As far as we are aware, this is the first
description of a reproducible association between a common
DDAH1 gene variation and human disease.
Table 4 | Coefficients for the variables in the baseline (nongenetic) multivariable multilevel model of eGFR through the follow-
up period
Coefficient in model of eGFR ml/min per 1.73m2
Variable LACKABO CRISIS
Age, per year Estimate 0.01 0.12**
95% CI 0.19 to 0.17 0.21 to 0.03
Sex, if female Estimate 15.91*** 5.25***
95% CI 21.73 to 10.10 7.84 to 2.65
UPE, per mg/mmol (LACKABO), per g per 24 h (CRISIS) Estimate 0.01 2.66***
95% CI 0.02 to 0.00 3.39 to 1.92
Time, per year Estimate 0.83 1.33***
95% CI 1.80 to 0.14 1.66 to 1.00
UPE Time, per mg/mmol per year (LACKABO), per g/24 h per year (CRISIS) Estimate 0.02*** 0.27***
95% CI 0.02 to 0.01 0.45 to 0.08
Abbreviations: CRISIS, Chronic Renal Insufficiency Standards Implementation Study; eGFR, estimated glomerular filtration rate; LACKABO, London Arterial Calcification,
Kidney and Bone Outcomes; MDRD, Modification of Diet in Renal Disease Study; UPE, urinary protein excretion.
Coefficients from the multivariate multilevel model with random slope and intercept (unstructured covariance matrix) are shown. Variance in eGFR—between subject
(baseline): LACKABO, 14.96ml/min per 1.73m2 (95% CI, 13.17–16.99); CRISIS, 16.57ml/min per 1.73m2 (95% CI, 15.65–17.53); between subject (over time): LACKABO, 3.29ml/
min per 1.73m2 per year (95% CI, 2.56–4.38); CRISIS, 2.56ml/min per 1.73m2 per year (95% CI, 2.19–2.92); within subject: LACKABO, 3.56ml/min per 1.73m2 (95% CI, 3.35–3.78);
CRISIS, 5.38ml/min per 1.73m2 (95% CI, 5.17–5.60). Examination of residuals in LACKABO suggested a good model fit. When running the same multilevel model in CRISIS
residual errors were particularly large for MDRD eGFR460ml/min per 1.73m2. The lack of prediction of actual GFR460ml/min per 1.73m2 by the MDRD equation has been
described previously (Levey et al.26). A sensitivity analysis for CRISIS was conducted omitting observations with MDRD eGFR460ml/min per 1.73m2. This reduced the residual
variance and gave an adequate model fit with the main conclusions of the analysis unchanged. The more conservative model (wider standard errors) based on the full data
set is reported.
**Po0.01; ***Po0.005.
Table 5 | Impact of DDAH genotype on eGFR through the follow-up period when added to the baseline multivariate model
Effect of genotype on baseline
eGFR, ml/min per 1.73m2
Effect of genotype on eGFR over time,
ml/min per 1.73m2 per year
SNP LACKABO CRISIS LACKABO CRISIS
rs805304
Per A allele, estimate 0.11 0.63 0.46 0.29
95% CI 3.81 to 4.04 1.29 to 2.56 0.72 to 1.64 0.73 to 0.15
rs7555486
Per T allele, estimate 2.23 1.05 1.89*** 0.35
95% CI 6.56 to 2.09 3.06 to 0.97 0.47 to 3.30 0.80 to 0.10
rs11486381
Per A allele, estimate 0.89 0.05 0.63 0.01
95% CI 6.56 to 2.09 1.73 to 1.84 0.54 to 1.80 0.40 to 0.41
rs17384213
Per G allele, estimate 1.59 0.51 1.18* 0.80**
95% CI 2.66 to 5.84 1.91 to 2.95 2.35 to 0.02 1.35 to 0.25
Abbreviations: CRISIS, Chronic Renal Insufficiency Standards Implementation Study; eGFR, estimated glomerular filtration rate; LACKABO, London Arterial Calcification,
Kidney and Bone Outcomes; SNP, single nucleotide polymorphism.
Restricted, white-only subjects. The variables included in the baseline multivariate model are shown in Table 4. Coefficients for genotype and genotype time interaction are
shown. There were no significant associations between the genotypes at rs233112, rs233128, or rs11161614 and eGFR at baseline or eGFR over time (all examined in the
LACKABO cohort only).
*Po0.05; **Po0.01; ***Po0.005. No formal correction for multiple testing was made. Coefficients for rs17384213 in LACKABO with inclusion of logADMA and
logADMA time in the model: baseline eGFR, 3.33ml/min per 1.73m2 per year, 95% CI, 1.05 to 7.71; eGFR over time, 1.43ml/min per 1.73m2 per year, 95% CI, 2.62 to
0.23. No genotype sex interaction was detected in this model.
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The use of a multivariable multilevel technique to model
eGFR showed the quantitative impact of UPE on the rate of
decline of kidney function, and our data suggest the effect of
gene variation in DDAH1 is independent of this established
risk factor. In addition, the lack of association between
DDAH1 SNPs and either BP or number of antihypertensive
treatments implies that DDAH1 is not exerting an effect
through exacerbating systemic hypertension. This is further
supported by the robustness of the genetic effect in the
sensitivity analyses. The estimated impact of genetic variation
in DDAH1 on eGFR over time is large (41.5ml/min per
1.73m2 per year between subjects with the rs17384213 AA
and GG genotypes) suggesting that our data reflect a
significant clinical as well as statistical effect.
The rs17384213 SNP is in strong linkage disequilibrium
with other SNPs throughout intron 1 (Figure 2). For
instance, in LACKABO, all the subjects with the (rare)
rs17384213 AA genotype also had the (common) rs7555486
TT genotype, which may explain the finding of an effect of
rs7555486 on eGFR in LACKABO that was not confirmed in
the larger CRISIS cohort. Furthermore, the large genetic area
tagged by the rs17384213 SNP means identification of the
specific regulatory sequence(s) will require substantial further
investigation.
These data appear to conflict with the relationship
described between ADMA and kidney outcomes in the obser-
vational studies where higher ADMA levels were associated
with progression to a composite end point.4,5 Plasma ADMA
levels are likely to be confounded by a number of biological
and environmental influences. For this reason we decided to
use a genetic approach, investigating the impact of variation
in the DDAHs, to establish any causal role for this pathway in
the progression of CKD. In addition, we used repeated
measures of a quantitative trait (eGFR) as an outcome
measure to maximize the study power.
It is unclear why our findings apparently differ from the
earlier human observational studies. One possibility is that
plasma concentrations may not accurately reflect local levels
of endogenous nitric oxide synthase inhibitors meaning that
circulating ADMA levels are not a useful reflection of renal
nitric oxide synthase inhibition. Although we could not
detect a difference in mortality rates between genotypes at
any of the DDAH1 loci in the short follow-up period of this
study, it is possible that there are differential effects of
ADMA-modulating DDAH1 SNPs on renal and cardiovas-
cular outcomes. Furthermore, the prevalence of the
rs17384213 genotype is low and the number of subjects with
this genotype in other smaller observational studies may be
too small to observe an effect on outcomes.
The rs17384213 GG genotype, which was associated with
steepest decline in eGFR in LACKABO and CRISIS, was also
associated with an increase in DDAH1 mRNA in renal
allograft tissue. Furthermore, healthy men carrying the
rs17384213 G allele had lower plasma ADMA compared to
those with the AA genotype in the EARSII study and a similar
trend was observed in LACKABO subjects. Although when
considered individually all three of these analyses are of
borderline statistical significance (without formal correction
for multiple testing; Figures 1a and b), the consistent impact
of the rs17384213 SNP on two different intermediate
variables (i.e., DDAH1 expression and plasma ADMA) in a
total of three independent data sets provides convincing
evidence for the direction of effect. Taken together, these data
(1) provide a compelling argument against a causal role for
increased circulating ADMA and (2) suggest an action for
DDAH1, in the common pathway of eGFR decline in the
context of CKD.
Two rodent studies suggest that over expression of
DDAH1 (with an associated fall in circulating ADMA)
retards renal injury in models of CKD.13,14 In contrast, our
data would suggest that reduced DDAH1 is associated with
preservation of renal function in man. Thus the ubiquitous
high levels of expression of DDAH1 in short-term rodent
studies may not adequately reflect the impact of altered
DDAH1 levels in human health and disease.
This study has several limitations. It would be interesting
to quantify ADMA directly in human kidney tissue of
different DDAH1 genotypes but this was not technically
possible because of the limited amount of biopsy material
available. In addition, the human allograft sample size was
small so the analysis had to be conducted with the hetero-
zygous and rare homozygous groups combined and this
tissue had been subject to a number of immune and
pharmacological insults. Confirmation of the relationship
between rs17384213 and DDAH1 expression in a larger number
of human tissue samples would therefore be desirable.
Although investigation of the SNP mRNA relationship
should ideally be conducted in other tissues, this is not
straightforward. DDAH1 is not expressed in leukocytes,11
and ethical and logistical obstacles prevent analysis of healthy
native human kidney tissue.
These data are further limited by the fact that different
aspects of this study were conducted in different populations
with differing baseline characteristics. Differences in age,
kidney function, underlying kidney disease, and collection of
follow-up data between the cohorts mean that several
outcome measures are not directly comparable across the
study groups. It is also important to replicate these findings
in cohorts of non-white CKD patients to confirm the
relevance of DDAH1 in other racial groups. This study was
designed to establish the impact of DDAH and ADMA on
decline in kidney function in patients with established CKD.
To establish whether variation at the rs17384213 locus in
DDAH1 represents a risk factor for renal disease in general
will require additional population-based case–control studies.
Furthermore, follow-up was relatively short. The impact of
ADMA-modulating DDAH1 variation on the incidence of
cardiovascular events and patient survival over a longer
follow-up period would be of particular interest.
The mechanisms by which DDAH1 mediates loss of
kidney function remain unclear. Although these data suggest
increases in circulating ADMA do not mediate this process,
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whether DDAH1 exacerbates renal decline by increasing local
ADMA metabolism or through a methylarginine-indepen-
dent pathway requires further investigation. A number of
factors have been proposed to have a role in the common
pathway of decline in renal function in CKD, but few
therapies are available or in development.20 In summary,
results of our study imply a role for DDAH1 in mediating
loss of kidney function independent of established risk
factors such as proteinuria. A better understanding of the role
of DDAH1 may lead to the development of novel therapeutic
strategies aimed at retarding the progression of CKD.
PATIENTS AND METHODS
Study participants
Research ethics committee approvals (and National Health
Service management approval, where appropriate) were
in place for all three epidemiological studies and the allograft
biopsy study. All studies were conducted in accordance with
the Declaration of Helsinki Principles and written informed
consent was obtained from all subjects (or next of kin where
transplant donors had died).
Transplant tissue and donor DNA were available from 21
of 45 renal allograft recipients (receiving kidneys from 20
donors whose families had all consented for donor tissue to
be used in research) enrolled in a study during 2007 and 2008
to investigate predictors of chronic allograft injury at the
Royal Free Hampstead NHS Trust (RFHNHST). Protocol
biopsies in allograft recipients were performed as per routine
clinical practice but a 2mm section of microscopically
confirmed cortex was placed immediately in RNALater
(Qiagen, West Sussex, UK), and stored at 70 1C. Samples
showing pyelonephritis or rejection on subsequent histolo-
gical analysis were excluded.
The EARSII study consists of 407 white male students aged
18–28 with no documented cardiovascular disease whose
fathers had suffered from a proven myocardial infarction
with an equal number of white age-matched controls, all
recruited from European universities in 1993.21 No hetero-
geneity was detected in ADMA levels between cases and
controls, therefore the association between genotype and
plasma ADMA concentrations was examined in the pooled
population.
The LACKABO study was designed to investigate the
natural history of arterial calcification in CKD patients. A
total of 269 subjects were recruited at the RFHNHST between
2004 and 2007. All subjects were 18 or older at the time of
recruitment with stage 2–5 CKD (not on renal replacement
therapy) of varied etiology. Baseline UPE, estimated using the
protein/creatinine ratio, and baseline and follow-up bio-
chemistry were performed by a single clinical chemistry
laboratory. Biochemistry samples were collected at all clinical
visits (with follow-up intervals varying between subjects,
depending on clinical need) until September 2008.
The CRISIS cohort is a prospective observational study
designed to investigate the epidemiology of CKD in subjects
referred to nephrological care in Greater Manchester (eGFR
p60ml/min and 410ml/min at recruitment, not on renal
replacement therapy). Baseline UPE, estimated by 24 h
collection, and baseline and follow-up biochemistry were
performed by a single-hospital clinical chemistry laboratory.
Recruitment began in October 2002, follow-up biochemistry
was performed annually, and results up to October 2008 were
included in this analysis.
Creatinines were measured by the respective clinical
chemistry laboratories using an isotope dilution mass
spectrometry traceable Jaffe´ method in both centers although
conversion to an isotope dilution mass spectrometry trace-
able method occurred during the follow-up period in CRISIS.
A retrospective adjustment was therefore applied by the
laboratory to all creatinine measurements in CRISIS retrieved
before this date. BP was measured using an oscillometric
device at baseline in both CKD cohorts. Racial group in both
CKD cohorts was self-reported.
Laboratory methods
DNA was extracted from leukocytes obtained from whole
blood. SNPs in both DDAH1 and DDAH2 were selected using
Genome Variation Server.18 SNPs were selected to obtain
maximal coverage where minor allele frequencies were X0.2
and an r2 threshold of 0.8 for tag SNPs. Genotyping by PCR
was performed using fluorescent probes as per the manu-
facturer’s instructions (SNP Assay Genotyping Assays;
Applied Biosystems, Cheshire, UK). All genotypes were
determined with the investigator masked to sample origin.
DDAH1 mRNA levels were determined in allograft tissue
by real-time reverse-transcription quantitative polymerase
chain reaction performed as previously described22 (Supple-
mentary Table 4 for primer sequences). DDAH mRNA was
normalized to the geometric mean of the control genes
showing maximal stability.23 DDAH1 and DDAH2 PCR
products were confirmed by direct sequencing. All samples
were analyzed blind to donor genotype.
Asymmetric dimethylarginine was quantified using high-
performance liquid chromatography as previously described
in LACKABO24 and EARSII25 studies. eGFR was calculated
from the serum creatinine using the four-variable Modifica-
tion of Diet in Renal Disease Equation.26 Subjects were
censored at death or commencement of renal replacement
therapy.
Statistical methods
For analysis of the transplant tissue study, the rare
homozygote donors were combined with heterozygote
donors (as we predicted low numbers of rare homozygotes
in the donor group). The significance of the relationship
between relative DDAH1 mRNA levels and donor genotype
was examined using an unpaired t-test. ADMA values were
log-transformed for analysis as the data were positively
skewed. The significance of the association between ADMA
and genotype was examined using analysis of variance
(ANOVA) after adjustment for age in LACKABO and age,
case–control status, and region of origin in EARSII. The
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genotype–ADMA relationship should not be confounded by
sex (as the DDAH1 gene is on chromosome 1), but as there
were no women in the EARSII study an analysis investigating
the differences between men and women in the genetic model
of ADMA in LACKABO was also performed.
Primary analyses were restricted to the white-only
subgroups of LACKABO and CRISIS to avoid confounding
of genetic effects by ethnicity. In LACKABO, EARSII, and
CRISIS the frequency of alleles at each locus was examined
and the Fisher’s exact test was used to detect significant
deviation from Hardy–Weinberg equilibrium.
Associations between genotype and potential biological
mediators of eGFR decline (renal diagnosis, presence of
diabetes, SBP, DBP, and UPE) were examined using w2,
ANOVA, and Kruskall–Wallis tests.
To investigate the impact of gene variation on renal
function over time, we modeled the outcome variable, eGFR,
using a two-level hierarchical structure (repeated measure-
ments at level 1 nested within individuals at level 2)27 with an
unstructured covariance matrix. Initially a nongenetic base-
line model was fitted including the a priori confounders age
and sex. A full random effects model showed an improved fit
(as indicated by the 2log likelihood ratio) compared to a
random intercept model. The baseline multilevel model
predicting eGFR included age, sex, time, and UPE with a
UPE time interaction. As no associations between DDAH
genotype and DBP, SBP, or number of antihypertensives were
found, these were not included in the model although
sensitivity analysis including these parameters was performed
after the final model including genotype had been fitted. To
retain model parsimony no three-way interactions were
fitted. Level 1 and level 2 residuals were examined for
deviation from a normal distribution. Genotype at each SNP
was added one at a time to the baseline multilevel model
assuming an additive (co-dominant) effect of each allele on
eGFR. The effect of genotype on eGFR decline was quantified
by the addition of a genotype time interaction. A further
exploratory analysis was performed at locus where a
logADMA and a logADMA time interaction were added
to the genetic (rs17384213) model of eGFR in LACKABO. No
formal corrections for multiple testing were made.
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